Please assess the completion status of the following clinical trial:

Trial Title: Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with pulmonary arterial hypertension with New York Heart Association stage II - III disease will be eligible for recruitment in the patient portion of the trial. Interested healthy age matched volunteers will also be recruited.~Exclusion Criteria:~* Patients and volunteers will be excluded if they have significant co-morbidities including other cardiorespiratory disease, metabolic abnormalities including diabetes or thyroid disorders. They will be excluded if they cannot safely exercise and perform a six minute walk test or if they are wheelchair bound.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- PH with wasting (Type: None): This group of patients with idiopathic pulmonary arterial hypertension exhibit quadriceps wasting
- PH no wasting (Type: None): This groups of patients with idiopathic pulmonary arterial hypertension exhibit no evidence of muscle wasting
- Controls (Type: None): This group of volunteers does not have pulmonary arterial hypertension and would not be expected to have muscle wasting

Based on this trial design, predict the completion outcome and termination type (if applicable).